Pinatuzumab vedotin

From WikiMD's WELLNESSPEDIA

Diagram of Vedotin Antibody-Drug Conjugates

Pinatuzumab vedotin is an antibody-drug conjugate (ADC) designed for the treatment of certain types of cancer. It is a targeted therapy that combines a monoclonal antibody with a cytotoxic agent, specifically designed to deliver the drug directly to cancer cells, thereby minimizing damage to normal cells.

Mechanism of Action[edit]

Pinatuzumab vedotin consists of a monoclonal antibody that targets the CD22 antigen, which is commonly expressed on the surface of B-cell malignancies. The antibody is linked to a cytotoxic agent, monomethyl auristatin E (MMAE), via a protease-cleavable linker. Once the ADC binds to the CD22 antigen on the surface of a cancer cell, it is internalized and the linker is cleaved, releasing MMAE into the cell. MMAE disrupts the microtubule network, leading to cell cycle arrest and apoptosis.

Clinical Development[edit]

Pinatuzumab vedotin has been evaluated in clinical trials for the treatment of non-Hodgkin lymphoma (NHL), particularly in patients with relapsed or refractory disease. The ADC has shown promise in targeting CD22-positive B-cell malignancies, offering a potential therapeutic option for patients who have exhausted other treatments.

Side Effects[edit]

As with many cancer therapies, pinatuzumab vedotin can cause a range of side effects. Common adverse effects include peripheral neuropathy, fatigue, nausea, and myelosuppression. The severity of side effects can vary depending on the dosage and the individual patient's response to the treatment.

Future Directions[edit]

Research is ongoing to explore the full potential of pinatuzumab vedotin in combination with other therapies, as well as its efficacy in different subtypes of B-cell malignancies. The development of ADCs like pinatuzumab vedotin represents a significant advancement in the field of targeted cancer therapy, offering hope for more effective and less toxic treatment options.

Related Pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Pinatuzumab_vedotin&oldid=6630348"